Ferroximend Information

Over 20% of irradiated bone fractures fail to heal. A major cause of failure is lack of vasculature. Ferroximend has developed an iron-chelating gel that activates the Hif-1alpha pathway and leads to increased neovasculature at the break site, leading to increased bone cell attachment, enhanced mineral deposition, and facilities new and stronger bone formation. Ferroximend's produce is a bioabsorbable slow-release gel that can be injected once at the time of initial break treatment to accelerate bone formation.